Replies to post #208985 on Biotech Values

[ghmm]

SRPT:

I don't have any specific revenue projects in the short term. I am general a very long term shareholder so I look at this way:
~1500 Exon 51 Amenable patients in the US
Say can get 2/3 reimbursed
Average price I think will be 500k++ (wouldn't be surprised at 600-700 especially if can get non-ambulatory reimbursed).
Their EV assuming 150-200M for Voucher is a bit over 1B
So looking at 500M+ opportunity for US and putting no value on everything else (Europe, x-EU/US, pipeline) the company is 2x peek US only sales which I think they can get too relatively soon (~2-3 years).

I didn't mention another thing I really like about Ed Kaye is his style/approach not just with dealing with regulators (which is much better than his predecessor), licensing/partnering but other aspects too like willingness to negotiate a royalty with BMRN.

Those are all rough back of the hand calculations. With some luck on reimbursement and penetration may get double that in peek sales. So I see a lot of upside potential to the stock and again we are just talking US Exondys 51

[masterlongevity]

i find the pricing of $srpt etep to be outrageous and more egregigous thatn Marathons pricing of deflazacort. At least we know deflazacort works